The Full Risk–Benefit Balance Behind the First Covid-19 Vaccine
The FDA’s first EUA for a Covid-19 vaccine rested on its determination that the benefits of the Pfizer–BioNTech vaccine outweighed its risks. Yet the trial report did not bring those together within a common framework. I did—and what I found was startling.
The Full Risk–Benefit Balance Behind the First Covid-19 Vaccine Continue Reading











